Lumos Pharma LLC, formerly known as, Lumos Pharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its lead product candidate, LUM-201, is an orally administered growth hormone secretagogue intended for the treatment of Pediatric Growth Hormone Deficiency (PGHD). The Companyâ€™s pipeline includes programs targeting growth hormone-related disorders and is supported by data from multiple clinical trials. Lumos Pharma engaged in strategic partnerships to expand its portfolio and leverage scientific in endocrinology, neurology, and metabolic diseases to advance drug development.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2024-12-11 EST			5-day change	1st Jan Change
4.340 ^USD	-.--%		-.--%	-

24-12-11	Lumos Pharma, Inc.(NasdaqGM:LUMO) dropped from NASDAQ Composite Index	CI
24-12-11	Double Point Ventures LLC completed the acquisition of Lumos Pharma, Inc.	CI

Market Cap	37.54M 32.47M 30.32M 27.81M 52.31M 3.57B 53.15M 356M 140M 1.79B 141M 138M 5.92B	P/E 2022	-0.97x	P/E 2023	-0.76x
Enterprise Value	2.04M 1.77M 1.65M 1.51M 2.85M 194M 2.89M 19.36M 7.6M 97.46M 7.67M 7.5M 322M	EV / Sales 2022	-24,220,550x	EV / Sales 2023	-5,033,462x
Free-Float	67.07%	Yield 2022 *	-	Yield 2023	-

24-12-11	Lumos Pharma, Inc.(NasdaqGM:LUMO) dropped from NASDAQ Composite Index	CI
24-12-11	Double Point Ventures LLC completed the acquisition of Lumos Pharma, Inc.	CI
24-12-11	Lumos Pharma, Inc.(NasdaqGM:LUMO) dropped from S&P TMI Index	CI
24-11-21	Lumos Pharma, Inc. Announces Updated Phase 2 OraGrowtH Data Presented at ESPE 2024	CI
24-11-07	Lumos Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-10-24	HC Wainwright Downgrades Lumos Pharma to Neutral From Buy, Adjusts Price Target to $4.25 From $28	MT
24-10-23	Lumos Pharma Says it has Agreed to be Acquired by a Double Point Ventures Unit and Taken Private	MT
24-10-23	Double Point to Buy Lumos Pharma for $38 Million as FDA OKs Lumos Drug Trial	DJ
24-10-22	Double Point Ventures LLC entered into a definitive merger agreement to acquire Lumos Pharma, Inc. for $36.9 million.	CI
24-08-02	Oppenheimer Adjusts Lumos Pharma Price Target to $13 From $16, Maintains Outperform Rating	MT
24-08-01	Lumos Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-08-01	Lumos Pharma, Inc., Q2 2024 Earnings Call, Aug 01, 2024
24-08-01	Earnings Flash (LUMO) LUMOS PHARMA Reports Q2 Revenue $488,000, vs. Street Est of $0.13M	MT

24-10-24	HC Wainwright Downgrades Lumos Pharma to Neutral From Buy, Adjusts Price Target to $4.25 From $28	MT
24-08-02	Oppenheimer Adjusts Lumos Pharma Price Target to $13 From $16, Maintains Outperform Rating	MT
23-12-11	Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating	MT
23-08-15	Cantor Fitzgerald Adjusts Lumos Pharma's Price Target to $10 From $14, Keeps Overweight Rating	MT
23-08-10	Oppenheimer Adjusts Lumos Pharma Price Target to $17 From $18, Maintains Outperform Rating	MT

Lumos Pharma, Inc. Stock

Stocks

LUMO

US55028X1090

Biotechnology & Medical Research

Valuation: Lumos Pharma, Inc.

Latest news : Lumos Pharma, Inc.

Analysts' recommendations: Lumos Pharma, Inc.

Press Releases: Lumos Pharma, Inc.

News in other languages: Lumos Pharma, Inc.

Course Extremes

Managers and Directors: Lumos Pharma, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

24-12-12	Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma	GL
24-11-25	Lumos Pharma : Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM 201 to 24 Months in PGHD and Correlation of Growth to LUM 201’s Unique Pulsatile Mechanism of Action Form 8 K	PU
24-11-21	Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action	AQ
24-11-21	Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action	GL
24-11-08	Lumos: Q3 Earnings Snapshot	AQ

19-12-20	Aktien New York Schluss: Rekorde - 'Anleger jagen dem Markt hinterher'
19-12-20	Aktien New York: Immer neue Rekorde - Investoren setzen auf die USA
15-07-31	Merck : Un vaccin contre Ebola se révèle efficace à 100%
15-07-31	NewLink Genetics : Premiers résultats du vaccin anti-Ebola "prometteurs"-OMS
15-01-08	Ebola-Essais cliniques en janvier et février en Afrique - OMS

Manager	Title	Age	Since
Lori Lawley DFI	Director of Finance/CFO	42	2021-07-03
John McKew PSD	President	61	2021-07-31
Aleksandra K. Bruchey COO	Chief Operating Officer	-	2022-04-30

Director	Title	Age	Since
Christopher Uzpen BRD	Director/Board Member	-	2024-12-11
Daniel Yadegar BRD	Director/Board Member	-	-
Campbell Murray BRD	Director/Board Member	50	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/12/24	John McKew	Issuer sale	Chairperson	255,142	2.9501%
12/12/24	SHVMS, LLC	Issuer sale	Company	730,446	8.4458%
12/12/24	Bradley Powers	Issuer sale	Compliance Officer	89,807	1.0384%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LUMOS PHARMA, INC.	-.--%	-.--%	-.--%	+36.05%	37.54M
WUXI APPTEC CO., LTD.	+8.49%	+20.55%	+70.77%	+110.32%	68.12B
ARGENX SE	+1.25%	+2.44%	+34.27%	+70.43%	55.18B
INSMED INCORPORATED	-1.09%	+32.96%	+19.67%	+494.56%	28.63B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+56.20%	+6.03%	23.99B
BIONTECH SE	+2.72%	+3.41%	-16.11%	-7.96%	23.53B
GENMAB A/S	+6.50%	+7.56%	+44.65%	-21.73%	18.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+33.87%	+693.38%	16.44B
PHARMAESSENTIA CORPORATION	-3.88%	+16.98%	+199.30%	+359.77%	15.83B
EXELIXIS, INC.	+3.58%	+1.96%	+43.35%	+163.76%	13.4B
Average	+3.46%	+10.51%	+48.60%	+190.46%	26.36B
Weighted average by Cap.	+4.36%	+13.09%	+50.68%	+168.46%

	2022	2023
Net sales	1.52 1.32 1.23 1.13 2.12 144.95 2.16 14.43 5.67 72.65 5.72 5.59 240.18	2.05 1.77 1.66 1.52 2.86 195.2 2.9 19.44 7.63 97.84 7.7 7.53 323.45
Net income	-31.06M -26.87M -25.09M -23.02M -43.29M -2.96B -43.98M -294M -116M -1.48B -117M -114M -4.9B	-34.03M -29.44M -27.49M -25.22M -47.44M -3.24B -48.19M -323M -127M -1.62B -128M -125M -5.37B
Net Debt	-67.13M -58.06M -54.22M -49.74M -93.56M -6.39B -95.04M -636M -250M -3.2B -252M -247M -10.59B	-35.49M -30.7M -28.67M -26.3M -49.47M -3.38B -50.25M -336M -132M -1.69B -133M -130M -5.6B

3 years	1.37	4.58
5 years	1.37	11.52
10 years	1.37	36.72